Compare Prodia Diagnostic Line Tbk (PRDL) vs Reksa Dana Indeks BNP Paribas IDX Growth30 ETF (XBIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prodia Diagnostic Line Tbk vs Reksa Dana Indeks BNP Paribas IDX Growth30 ETF — how do they compare? Prodia Diagnostic Line Tbk trades at Rp236 (market cap 428.75B, 13.83M 24h volume), while Reksa Dana Indeks BNP Paribas IDX Growth30 ETF trades at Rp600 (market cap 120M). The key difference: Prodia Diagnostic Line Tbk is far larger — about 3572.9× Reksa Dana Indeks BNP Paribas IDX Growth30 ETF's market cap. Which is the better fit depends on your goals.
| PRDL | XBIG | |
|---|---|---|
Market Cap | 428.75B | 120M |
Volume | 13.83M | — |
Lot | 138.27K | — |
Turnover | 3.27B | — |
Average Price | 236.62 | — |
Value | 3.27B | — |
Indicative Equilibrium Price | 236 | — |
Indicative Equilibrium Volume | 1.74K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prodia Diagnostic Line Tbk
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →
